{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T13:30:00Z","timestamp":1793626200834,"version":"4.5.1"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ymthe.2026.10.017","type":"journal-article","created":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T09:51:00Z","timestamp":1792230660000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["IL-12-producing iPSC-derived antigen-presenting cells enhance antitumor immunity and enable off-the-shelf immunotherapy"],"prefix":"10.1016","author":[{"given":"Masateru","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaigeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Mashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keigo","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Kariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Hagiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eri","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sena","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Osako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0980-4021","authenticated-orcid":false,"given":"Ryo","family":"Nakaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Nakatsura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0622-7682","authenticated-orcid":false,"given":"Satoshi","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-4586","authenticated-orcid":false,"given":"Shin","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitsu","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9066-1288","authenticated-orcid":false,"given":"Hideki","family":"Ohdan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9622-0934","authenticated-orcid":false,"given":"Yasushi","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.10.017_bib1","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.10.017_bib2","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","article-title":"Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma","volume":"25","author":"Liu","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2026.10.017_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2026.10.017_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The Immunobiology of the Interleukin-12 Family: Room for Discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.10.017_bib5","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1158\/1078-0432.CCR-18-0381","article-title":"Revisiting Interleukin-12 as a Cancer Immunotherapy Agent","volume":"24","author":"Berraondo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.10.017_bib6","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1016\/j.cell.2021.02.048","article-title":"Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis","volume":"184","author":"Kaczanowska","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2026.10.017_bib7","first-page":"409","article-title":"Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies","volume":"3","author":"Atkins","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.10.017_bib8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41565-023-01580-3","article-title":"Inhalable extracellular vesicle delivery of IL-12 mRNA to treat lung cancer and promote systemic immunity","volume":"19","author":"Liu","year":"2024","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.ymthe.2026.10.017_bib9","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000710","article-title":"Oncolytic vaccinia virus delivering tethered IL-12 enhances antitumor effects with improved safety","volume":"8","author":"Ge","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.10.017_bib10","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1038\/s43018-020-0095-6","article-title":"Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity","volume":"1","author":"Li","year":"2020","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2026.10.017_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001356","article-title":"Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses","volume":"8","author":"Brempelis","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.10.017_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000210","article-title":"Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models","volume":"8","author":"Zhang","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.10.017_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144195","article-title":"A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells","volume":"131","author":"Veatch","year":"2021","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.10.017_bib14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ccell.2019.10.006","article-title":"Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8(+) T Cells","volume":"36","author":"Etxeberria","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2026.10.017_bib15","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1172\/JCI68395","article-title":"IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity","volume":"123","author":"Carreno","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.10.017_bib16","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1158\/1078-0432.CCR-15-1399","article-title":"Dendritic Cell-Based Immunotherapy: State of the Art and Beyond","volume":"22","author":"Bol","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2026.10.017_bib17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1200\/JCO.2010.30.7744","volume":"29","author":"Okada","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.10.017_bib18","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1200\/JCO.2005.00.463","article-title":"Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas","volume":"23","author":"Mazzolini","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.10.017_bib19","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1158\/2326-6066.CIR-14-0117","article-title":"Generation of mouse pluripotent stem cell-derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells","volume":"3","author":"Zhang","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2026.10.017_bib20","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.celrep.2019.08.086","article-title":"Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1(+) Dendritic Cells","volume":"29","author":"Tsuchiya","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.10.017_bib21","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1814620","article-title":"Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response","volume":"9","author":"Mashima","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2026.10.017_bib22","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/s41568-021-00363-z","article-title":"Interleukins in cancer: from biology to therapy","volume":"21","author":"Briukhovetska","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2026.10.017_bib23","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s43018-023-00668-y","article-title":"Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy","volume":"5","author":"Ghasemi","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2026.10.017_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.172062","article-title":"Single-cell transcriptomics analysis of proliferative diabetic retinopathy fibrovascular membranes reveals AEBP1 as fibrogenesis modulator","volume":"8","author":"Corano Scheri","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.ymthe.2026.10.017_bib25","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1158\/2159-8290.CD-15-0563","article-title":"Adaptive Immune Resistance: How Cancer Protects from Immune Attack","volume":"5","author":"Ribas","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2026.10.017_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12943-023-01873-0","article-title":"Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy","volume":"22","author":"Chehelgerdi","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ymthe.2026.10.017_bib27","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1093\/jrr\/rrw124","article-title":"Irradiation strongly reduces tumorigenesis of human induced pluripotent stem cells","volume":"58","author":"Inui","year":"2017","journal-title":"J. Radiat. Res."},{"key":"10.1016\/j.ymthe.2026.10.017_bib28","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.stem.2012.11.002","article-title":"Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation","volume":"12","author":"Nishimura","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2026.10.017_bib29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.stemcr.2016.01.005","article-title":"Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated V\u03b124 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells","volume":"6","author":"Kitayama","year":"2016","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.ymthe.2026.10.017_bib30","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1182\/blood.V97.9.2903","article-title":"Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes","volume":"97","author":"Arai","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2026.10.017_bib31","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2026.10.017_bib32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","article-title":"Generation of hypoimmunogenic T cells from genetically engineered allogeneic human induced pluripotent stem cells","volume":"5","author":"Wang","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2026.10.017_bib33","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41551-018-0250-x","article-title":"Towards superior dendritic-cell vaccines for cancer therapy","volume":"2","author":"Saxena","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2026.10.017_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002931","article-title":"Phase Ib study of patients with metastatic castrate-resistant prostate cancer treated with different sequencing regimens of atezolizumab and sipuleucel-T","volume":"9","author":"Dorff","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2026.10.017_bib35","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1634\/stemcells.2007-0321","article-title":"Genetically manipulated human embryonic stem cell-derived dendritic cells with immune regulatory function","volume":"25","author":"Senju","year":"2007","journal-title":"Stem Cells"},{"key":"10.1016\/j.ymthe.2026.10.017_bib36","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/gt.2011.22","article-title":"Generation of dendritic cells and macrophages from human induced pluripotent stem cells aiming at cell therapy","volume":"18","author":"Senju","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.10.017_bib37","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau4292","article-title":"Direct reprogramming of fibroblasts into antigen-presenting dendritic cells","volume":"3","author":"Rosa","year":"2018","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ymthe.2026.10.017_bib38","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ccell.2021.11.012","article-title":"Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance","volume":"40","author":"Newell","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ymthe.2026.10.017_bib39","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2026.10.017_bib40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2026.10.017_bib41","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.immuni.2018.09.024","article-title":"Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-\u03b3 and IL-12","volume":"49","author":"Garris","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2026.10.017_bib42","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.10.017_bib43","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ymthe.2026.10.017_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.575597","article-title":"Localized Interleukin-12 for Cancer Immunotherapy","volume":"11","author":"Nguyen","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.10.017_bib45","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3389\/fimmu.2020.00938","article-title":"Myeloid Cell-Derived Arginase in Cancer Immune Response","volume":"11","author":"Grzywa","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.10.017_bib46","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","article-title":"Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade","volume":"20","author":"Miller","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.ymthe.2026.10.017_bib47","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.celrep.2018.01.072","article-title":"Suppression of Tcf1 by Inflammatory Cytokines Facilitates Effector CD8 T Cell Differentiation","volume":"22","author":"Danilo","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2026.10.017_bib48","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/nrc3034","article-title":"The tumorigenicity of human embryonic and induced pluripotent stem cells","volume":"11","author":"Ben-David","year":"2011","journal-title":"Nat. Rev. Cancer"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626008750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626008750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:56:05Z","timestamp":1793624165000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626008750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":48,"alternative-id":["S1525001626008750"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.10.017","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IL-12-producing iPSC-derived antigen-presenting cells enhance antitumor immunity and enable off-the-shelf immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}